Zobrazeno 1 - 10
of 1 654
pro vyhledávání: '"borderline resectable"'
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background The current treatment strategies for borderline resectable esophageal squamous cell carcinoma remain controversial. This study aimed to evaluate the efficacy and safety of programmed cell death 1 inhibitors combined with chemother
Externí odkaz:
https://doaj.org/article/36074a35c5434dd39bc3f4e66f21dc65
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2063-2076 (2024)
Yuan Shi,* Kai Chen,* Xinlin Li,* Xiaodong Li, Xu Feng, Xinhua Wu, Shiguai Qi, Zhengrong Shi Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China*T
Externí odkaz:
https://doaj.org/article/4eaf153d87f346b9bc0cda006ea6c5b5
Autor:
Nikhil Chervu, Shineui Kim, Sara Sakowitz, Nguyen Le, Saad Mallick, Hanjoo Lee, Peyman Benharash, Timothy Donahue
Publikováno v:
Surgery Open Science, Vol 20, Iss , Pp 101-105 (2024)
Background: Multiagent neoadjuvant chemotherapy (NAT) has been linked with improved survival for locally advanced (LA) or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). However, the existence of disparities in its utilization rem
Externí odkaz:
https://doaj.org/article/220fd89c146b46008678221e4fc1f85f
Autor:
Ankit Vishwani, Bipin Thomas Varghese, Shaji Thomas, Ashima Kumar, Japneet Kaur, Anukampa Sharma
Publikováno v:
Oral Oncology Reports, Vol 12, Iss , Pp 100683- (2024)
Background: Locally advanced borderline resectable oral cancer poses significant treatment challenges due to its infiltrative nature and high relapse rates, leading to poor prognosis. Neoadjuvant immunotherapy may offer a novel therapeutic approach,
Externí odkaz:
https://doaj.org/article/23ed01c581fe4e34b60780a7038a5e66
Autor:
Małgorzata Domagała-Haduch, Anita Gorzelak-Magiera, Łukasz Michalecki, Iwona Gisterek-Grocholska
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3291-3300 (2024)
Despite the advancements made in oncology in recent years, the treatment of pancreatic cancer remains a challenge. Five-year survival rates for this cancer do not exceed 10%. Among the reasons contributing to poor treatment outcomes are the oligosymp
Externí odkaz:
https://doaj.org/article/e1e3c6971220414f8badefc6ad22d464
Autor:
Hirofumi Akita, Kei Asukai, Yosuke Mukai, Shinichiro Hasegawa, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Masato Sakon, Hiroshi Wada, Hidenori Takahashi
Publikováno v:
BMC Surgery, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background In pancreatic ductal adenocarcinoma (PDAC), invasion of connective tissues surrounding major arteries is a crucial prognostic factor after radical resection. However, why the connective tissues invasion is associated with poor pro
Externí odkaz:
https://doaj.org/article/4910f2f40e364182a4da0c5065c759a3
Publikováno v:
Waike lilun yu shijian, Vol 29, Iss 01, Pp 54-60 (2024)
Objective To investigate the risk factors of early thromboembolism after pancreaticoduodenectomy with vein reconstruction. Methods The results of bedside ultrasonography and clinical data of 90 patients from Ruijin Hospital, Shanghai Jiao Tong Univer
Externí odkaz:
https://doaj.org/article/442c8b10a6a247b6a78a63c6909e87c0
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21199-21208 (2023)
Abstract Background The pancreatic index (PI) is a useful preoperative imaging predictor for pancreatic ductal adenocarcinoma (PDAC). In this retrospective study, we determined the predictive effect of PI to distinguish patients of pancreatic body/ta
Externí odkaz:
https://doaj.org/article/a586ffff6a114397b2e236f8c7542172
Autor:
Akiyuki Wakita, Satoru Motoyama, Yusuke Sato, Yushi Nagaki, Hiromu Fujita, Kohei Kemuriyama, Kenjiro Hayashi, Kazuhiro Imai, Hiroshi Nanjo, Yoshihiro Minamiya
Publikováno v:
Annals of Gastroenterological Surgery, Vol 7, Iss 6, Pp 904-912 (2023)
Abstract Aim Because the optimal treatment strategy for borderline resectable (cT3br) thoracic esophageal cancer patients remains unclear, it is of great interest whether preoperative neoadjuvant therapy for cT3br could achieve results comparable to
Externí odkaz:
https://doaj.org/article/42d6ee3685bb4878b6987e963cb66e86
Autor:
Ken‐ichi Okada, Kenjiro Kimura, Yo‐Ichi Yamashita, Kazuto Shibuya, Ippei Matsumoto, Sohei Satoi, Kazuhiro Yoshida, Yasuhiro Kodera, Takahiro Akahori, Seiko Hirono, Hidetoshi Eguchi, Mitsuhiro Asakuma, Masaji Tani, Etsuro Hatano, Hisashi Ikoma, Go Ohira, Hiromitsu Hayashi, Ke Wan, Toshio Shimokawa, Manabu Kawai, Hiroki Yamaue, The NAC‐GA investigators
Publikováno v:
Annals of Gastroenterological Surgery, Vol 7, Iss 6, Pp 997-1008 (2023)
Abstract Background Nab‐paclitaxel plus gemcitabine is a standard treatment for metastatic/locally advanced pancreatic cancer. The effectiveness of neoadjuvant therapy with nab‐paclitaxel plus gemcitabine (GnP‐NAT) in patients with borderline r
Externí odkaz:
https://doaj.org/article/86604cdf338e458589ae44c27f7b2e8a